176 related articles for article (PubMed ID: 6216863)
1. Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients.
Balch CM; Dougherty PA; Tilden AB
Ann Surg; 1982 Dec; 196(6):645-50. PubMed ID: 6216863
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin E2-mediated suppression of cellular immunity in colon cancer patients.
Balch CM; Dougherty PA; Cloud GA; Tilden AB
Surgery; 1984 Jan; 95(1):71-7. PubMed ID: 6229053
[TBL] [Abstract][Full Text] [Related]
3. Deficient immunity in head and neck cancer due to excessive monocyte production of prostaglandins.
Berlinger NT
Laryngoscope; 1984 Nov; 94(11 Pt 1):1407-10. PubMed ID: 6593559
[TBL] [Abstract][Full Text] [Related]
4. Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer.
McCormick KJ; Panje WR
Cancer Immunol Immunother; 1986; 21(3):226-32. PubMed ID: 3457630
[TBL] [Abstract][Full Text] [Related]
5. Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression.
Tilden AB; Balch CM
Surgery; 1982 Sep; 92(3):528-32. PubMed ID: 6287658
[TBL] [Abstract][Full Text] [Related]
6. Cellular immunity in Q fever: modulation of responsiveness by a suppressor T cell-monocyte circuit.
Koster FT; Williams JC; Goodwin JS
J Immunol; 1985 Aug; 135(2):1067-72. PubMed ID: 2409135
[TBL] [Abstract][Full Text] [Related]
7. Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell.
Wanebo HJ; Riley T; Katz D; Pace RC; Johns ME; Cantrell RW
Cancer; 1988 Feb; 61(3):462-74. PubMed ID: 2962730
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of lymphocyte response by prostaglandin-producing suppressor cells in patients with melanoma.
Murray JL; Kollmorgen GM
J Clin Immunol; 1983 Jul; 3(3):268-76. PubMed ID: 6224806
[TBL] [Abstract][Full Text] [Related]
9. Indomethacin enhancement of immunocompetence in melanoma patients.
Tilden AB; Balch CM
Surgery; 1981 Jul; 90(1):77-84. PubMed ID: 6972628
[TBL] [Abstract][Full Text] [Related]
10. Prostaglandin E2 (PGE2)-dependent suppression of interleukin alpha (IL-2) production in patients with major trauma.
Faist E; Mewes A; Baker CC; Strasser T; Alkan SS; Rieber P; Heberer G
J Trauma; 1987 Aug; 27(8):837-48. PubMed ID: 2956432
[TBL] [Abstract][Full Text] [Related]
11. Indomethacin sensitive suppressor cell activity in head and neck cancer patients pre- and postirradiation therapy.
Maca RD; Panje WR
Cancer; 1982 Aug; 50(3):483-9. PubMed ID: 7093891
[TBL] [Abstract][Full Text] [Related]
12. The role of prostaglandin E2 in immune suppression following injury.
Grbic JT; Mannick JA; Gough DB; Rodrick ML
Ann Surg; 1991 Sep; 214(3):253-62; discussion 262-3. PubMed ID: 1929607
[TBL] [Abstract][Full Text] [Related]
13. Lack of prostaglandin E2-mediated monocyte suppressive activity in newborn and mothers.
Fischer A; Durandy A; Mamas S; McCall E; Dray F; Griscelli C
Clin Exp Immunol; 1982 Aug; 49(2):377-85. PubMed ID: 6215198
[TBL] [Abstract][Full Text] [Related]
14. Distinct role of neonatal and adult monocytes in the regulation of the in vitro antigen-induced plaque-forming cell response in man.
van Tol MJ; Zijlstra J; Thomas CM; Zegers BJ; Ballieux RE
J Immunol; 1984 Oct; 133(4):1902-8. PubMed ID: 6381591
[TBL] [Abstract][Full Text] [Related]
15. In vitro inhibition of interleukin-2 production by peripheral blood lymphocytes from stage III melanoma patients by prostaglandin E2: enhancement of lymphocyte proliferation by exogenous interleukin-2 plus indomethacin.
Murray JL; Dowd J; Hersh EM
J Biol Response Mod; 1986 Feb; 5(1):12-9. PubMed ID: 3485703
[TBL] [Abstract][Full Text] [Related]
16. Inability of newborns' or pregnant women's monocytes to suppress pokeweed mitogen-induced responses.
Durandy A; Fischer A; Griscelli C
J Immunol; 1982 Feb; 128(2):525-9. PubMed ID: 6459380
[TBL] [Abstract][Full Text] [Related]
17. Separation of a population of human T lymphocytes that bind prostaglandin E2 and exert a suppressor activity.
Fischer A; Le Deist F; Durandy A; Griscelli C
J Immunol; 1985 Feb; 134(2):815-9. PubMed ID: 2856929
[TBL] [Abstract][Full Text] [Related]
18. The effect of prostaglandin and its inhibitor on antibody-dependent cellular cytotoxicity against human squamous cell carcinoma of head and neck.
Kim CD; Sung MW; Lee SJ; Heo DS; Yoon SJ; Kim KH
Anticancer Res; 1999; 19(1A):455-9. PubMed ID: 10226582
[TBL] [Abstract][Full Text] [Related]
19. 1,25-Dihydroxyvitamin D3 enhances prostaglandin E2 production by monocytes. A mechanism which partially accounts for the antiproliferative effect of 1,25(OH)2D3 on lymphocytes.
Koren R; Ravid A; Rotem C; Shohami E; Liberman UA; Novogrodsky A
FEBS Lett; 1986 Sep; 205(1):113-6. PubMed ID: 3462028
[TBL] [Abstract][Full Text] [Related]
20. Administration of a prostaglandin synthetase inhibitor associated with an increased immune cell infiltrate in squamous cell carcinoma of the head and neck.
Cross DS; Platt JL; Juhn SK; Bach FH; Adams GL
Arch Otolaryngol Head Neck Surg; 1992 May; 118(5):526-8. PubMed ID: 1571128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
